Compare WAVE & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAVE | CTSO |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.3M | 45.9M |
| IPO Year | 2021 | N/A |
| Metric | WAVE | CTSO |
|---|---|---|
| Price | $6.17 | $0.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $15.00 | $5.38 |
| AVG Volume (30 Days) | 12.6K | ★ 121.2K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $168,000.00 | ★ $36,979,520.00 |
| Revenue This Year | N/A | $9.51 |
| Revenue Next Year | $400.00 | $24.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 23.89 |
| 52 Week Low | $4.41 | $0.60 |
| 52 Week High | $17.38 | $1.61 |
| Indicator | WAVE | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 36.02 | 40.85 |
| Support Level | $6.39 | $0.60 |
| Resistance Level | $7.00 | $0.76 |
| Average True Range (ATR) | 0.28 | 0.06 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 16.22 | 19.04 |
Eco Wave Power Global AB is a Sweden-based wave energy company engaged in the development of a smart and cost-efficient WEC, technology that converts ocean and sea waves into clean electricity. Its WEC technology employs units of point absorber floating devices, referred to as floaters, which are installed on existing marine structures such as piers, breakwaters, and jetties, or in locations in which such marine structures are required. Geographical presence in Israel, USA and Mexico.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.